Dongkook wins Korean patent for sustained release formulations of octretide

Dongkook Pharm said on March 18 it won Korean patent for octreotide in sustained release form and its manufacturing method, following its development of octreotide injection last year.

Octreotide (brand name Sandostatin, Novartis Inc.) is an octapeptide hat mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagone and insulin than the na...